[HTML][HTML] Clinical Manifestations and Outcomes of Older patients with COVID-19: A Comprehensive Review
JE Lee, SY Kim, DK Kim, SI Lee - Tuberculosis and Respiratory …, 2024 - ncbi.nlm.nih.gov
The consequences of coronavirus disease 2019 (COVID-19) are particularly severe in older
adults with a disproportionate number of severe and fatal outcomes. Therefore, this …
adults with a disproportionate number of severe and fatal outcomes. Therefore, this …
[HTML][HTML] The safety and effectiveness of tocilizumab in older adult critically ill patients with COVID-19: a multicenter, cohort study
Objectives Evidence supports tocilizumab (TCZ) benefit and safety in adult patients with
severe COVID-19. However, its effectiveness in critically ill older adult patients remains …
severe COVID-19. However, its effectiveness in critically ill older adult patients remains …
The central role of extracellular vesicles in the mechanisms of thrombosis in COVID-19 patients with cancer and therapeutic strategies
H Jing, N Zuo, VA Novakovic, J Shi - Frontiers in Cell and …, 2022 - frontiersin.org
Cancer patients have increased SARS-CoV-2 susceptibility and are prone to developing
severe COVID-19 infections. The incidence of venous thrombosis is approximately 20% in …
severe COVID-19 infections. The incidence of venous thrombosis is approximately 20% in …
Proteomic analysis and identification reveal the anti-inflammatory mechanism of clofazimine on lipopolysaccharide-induced acute lung injury in mice
B Yang, Z Gao, QS Li, XY Zhang, L Song… - Inflammation …, 2022 - Springer
Background and objective Acute lung injury (ALI)/acute respiratory distress syndrome
(ARDS) was increasingly recognized as one of the most severe acute hyperimmune …
(ARDS) was increasingly recognized as one of the most severe acute hyperimmune …
Cytokine storm and translating IL-6 biology into effective treatments for COVID-19
T Li, D Wang, H Wei, X Xu - Frontiers of Medicine, 2023 - Springer
Abstract As of May 3, 2023, the Coronavirus disease 2019 (COVID-19) pandemic has
resulted in more than 760 million confirmed cases and over 6.9 million deaths. Several …
resulted in more than 760 million confirmed cases and over 6.9 million deaths. Several …
Quantitative SARS-CoV-2 RT-PCR and Bronchoalveolar Cytokine Concentrations Redefine the COVID-19 Phenotypes in Critically Ill Patients
MC Vazquez Guillamet… - Journal of Intensive …, 2024 - journals.sagepub.com
Rationale Recent studies suggest that both hypo-and hyperinflammatory acute respiratory
distress syndrome (ARDS) phenotypes characterize severe COVID-19-related pneumonia …
distress syndrome (ARDS) phenotypes characterize severe COVID-19-related pneumonia …
Cardiovascular Disease from Pathophysiology to Risk Estimation: Is Inflammation Estimated through Perivascular Attenuation on Computed Tomography the Key?
D Tuttolomondo, G Niccoli, C Martini, F D'Ascenzo… - Life, 2024 - mdpi.com
(1) Background: Systemic inflammation stands as a well-established risk factor for ischemic
cardiovascular disease, as well as a contributing factor in the development of cardiac …
cardiovascular disease, as well as a contributing factor in the development of cardiac …
[PDF][PDF] Therapeutic Impact of Tocilizumab in the Setting of Severe COVID-19; an Updated and Comprehensive Review on Current Evidence
A Rezabakhsh, F Mojtahedi… - Archives of …, 2024 - journals.sbmu.ac.ir
Introduction: The COVID-19 pandemic caused by SARS-CoV-2 has been the major health
concern in 2019 globally. Considering the severity and phase of the disease, various …
concern in 2019 globally. Considering the severity and phase of the disease, various …
Alpha‐1 adrenergic antagonists and the risk of hospitalization or death in non‐hospitalized patients with COVID‐19: A population‐based study
T Antoniou, D McCormack, M Tadrous… - Fundamental & …, 2024 - Wiley Online Library
Background Alpha‐1 receptor antagonists may interfere with IL‐6 signaling and could
therefore be a potential treatment for COVID‐19. However, the effectiveness of these drugs …
therefore be a potential treatment for COVID‐19. However, the effectiveness of these drugs …
[PDF][PDF] THE EVOLUTION AND TREATMENT OPTIONS OF PATIENTS WITH COVID-19 AND NEUROLOGICAL MANIFESTATIONS-A NARRATIVE REVIEW.
I Odajiu, D SANDU, EI Davidescu, BO Popescu - Farmacia, 2022 - farmaciajournal.com
COVID-19 is a multisystem disease with considerable heterogeneity of manifestations,
including neurological. Neurological manifestations occur in up to 2/3 of patients in the acute …
including neurological. Neurological manifestations occur in up to 2/3 of patients in the acute …